Feature | October 26, 2011| Dave Fornell

TAVI ROI Will Come From Surgical Referrals, Not TAVI

The Cardiopulmonary Research Science and Technology Institute (CRSTI) in Dallas, Texas, created two hybrid operating rooms (ORs) specifically for participation in the PARTNER trial for Edwards Sapien transcatheter aortic valve. The center has implanted more than 200 Sapien valves since it started in the trial in 2006.


Angela Riley, RT, CRSTI executive director, said the cost of transcatheter aortic valve implantation (TAVI) and the build out of the hybrid ORs will be prohibitive for most hospitals and the return on investment (ROI) is low. However, she said patients are drawn to facilities offering TAVI.


She said patient selection for TAVI is critical and many patients do not qualify. Her center screens four patients to get one who is suitable for TAVI. Most of those turned away undergo surgical valve replacement. While this is not a good ratio to base return on investment (ROI) for building a TAVI program, Riley said the real returns have come from tripling surgical referrals.


A better strategy to sell the costs of a TAVI program to hospital administrators is not to base ROI on TAVI procedures, but on the increased surgical valve repair volume from the referrals. “Even if patients do not qualify, they will usually stay with your hospital for other treatments,” she explained.

Related Content

FDA Approves IDE Study for Foldax Biopolymer Heart Valve Platform
News | Heart Valve Technology | February 18, 2019
Foldax Inc. announced the U.S. Food and Drug Administration (FDA) has granted investigative device exemption (IDE)...
Thubrikar Announces First-in-Human Implant of Optimum TAVI System
News | Heart Valve Technology | January 29, 2019
Thubrikar Aortic Valve Inc. announced the first human implant of the Optimum TAV using their transcatheter aortic valve...
Perceval Valve Offers Performance, Economic Advantages in Aortic Disease Treatment
News | Heart Valve Technology | January 29, 2019
LivaNova PLC announced the publication of three separate studies highlighting the performance of its sutureless aortic...
First Tendyne Transcatheter Mitral Valve Implanted in New York
News | Heart Valve Technology | January 28, 2019
Lenox Hill Hospital is the first hospital in New York City to successfully implant Abbott’s Tendyne transcatheter...
Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement
News | Heart Valve Technology | January 15, 2019
Boston Scientific Corp. and Edwards Lifesciences Corp. announced that the companies have reached an agreement to settle...
The implantation of a MitraClip is guided under live transesophageal echo (TEE). This image shows the operator moving the open clip into position and engaging the mitral valve leaflets. The clip appears as a arrowhead shape in the ultrasound with the leaflets coming off each side. Photo from a MitraClip procedure at the University of Colorado Hospital. Dr. Dominick Wiktor. The TEE is from a Philips Epiq system.

The implantation of a MitraClip is guided under live transesophageal echo (TEE). This image shows the operator moving the open clip into position and engaging the mitral valve leaflets. The clip appears as an arrowhead shape in the ultrasound with the leaflets coming off each side. Photo from a MitraClip procedure at the University of Colorado Hospital.

Feature | Heart Valve Technology | January 14, 2019 | Allen Atchley, M.D., FACC, The Chattanooga Heart Institute
Mitral regurgitation (MR) is one of the most common types of heart valve diseases in the United States, affecting app
JC Medical Announces First U.S. Treatment With J-Valve TAVR Device
News | Heart Valve Technology | January 07, 2019
January 7, 2019 — JC Medical announced the successful treatment of the first U.S.
Edwards' Sapien 3 Ultra Transcatheter Heart Valve Receives FDA Approval
Technology | Heart Valve Technology | January 02, 2019
Edwards Lifesciences Corp. announced that the Sapien 3 Ultra system has received U.S. Food and Drug Administration (FDA...
Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation
Feature | Heart Valve Technology | December 12, 2018
A jury in the U.S. District Court for the District of Delaware determined Dec. 11 that the Boston Scientific U.S....
Overlay Init